The evaluation of the efficacy of a switch from GnRH agonist to GnRH antagonist in prostate cancer patients who relapsed during combined androgen blockade. - The evaluation of the efficacy of a switch from GnRH agonist to GnRH antagonist in prostate cancer patients who relapsed during combined androgen blockade.

Tokai Urological Clinical Trial Group0 个研究点目标入组 50 人开始时间: 2014年3月27日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. receiving chemotherapeutic agents (including estramustine), corticosteroids, hormone agents except for GnRH agonist and non-steroidal antiandrogens, or investigational drugs 2. patients who never responded to CAB 3. patients with active multiple cancers 4. patients with clinical symptoms such as bone pain and nerve injury as a result of a spinal cord compression 5. prior treatment with local therapy (radical prostatectomy or radiotherapy) 6. patients with severe hepatic dysfunction (Child-Pugh class C) 7. patients with HIV or chronic active hepatitis B/C 8. history of acute myocardial infarction, severe or unstable angina, coronary or peripheral arterial revascularization, symptomatic congestive heart failure, cerebral vascular disease, transient ischemic attacks, or pulmonary embolism within 6 months before registration 9. patients with interstitial pneumonia or past history of interstitial pneumonia 10. patients with a brain tumor

发起方

Tokai Urological Clinical Trial Group